Cytogen

Cytogen develops technology that isolates living circulating tumor cells, cancer cells that travel through a patient's bloodstream, and uses them to help detect cancer, guide treatment choices, and monitor patient outcomes without a traditional tissue biopsy.

Its core platform, called Smart Biopsy™, provides analytical services and biomarker data to pharmaceutical companies developing new cancer drugs, supporting each stage from early-stage biomarker discovery through companion-diagnostic development. Research institutions also receive analysis data, kits, and collaborative research services. The company is listed on KOSDAQ, South Korea's tech-focused small-cap exchange.